Common Side Effects and Patient Concerns
Verzenio (abemaciclib) is a medication used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR/HER2-) advanced or metastatic breast cancer. As with any medication, Verzenio can cause side effects, some of which can be serious [1].
Common Side Effects:
1. Fatigue (40-50%): Fatigue is one of the most common side effects of Verzenio, with up to 50% of patients experiencing it.
2. Nausea (30-40%): Nausea is another common side effect, affecting between 30-40% of patients.
3. Diarrhea (30-40%): Diarrhea is a common side effect, occurring in about 30-40% of patients.
4. Abdominal Pain (20-30%): Abdominal pain or discomfort is experienced by about 20-30% of patients.
5. Nausea, Vomiting (20-30%): Some patients experience nausea and vomiting, affecting around 20-30% of them.
Serious Side Effects and Patient Concerns:
1. Leukopenia (low white blood cell count): Verzenio can cause a decrease in white blood cell count, increasing the risk of infections [2].
2. Thrombocytopenia (low platelet count): The medication can also cause a decrease in platelet count, making bleeding more likely [2].
3. Hypersensitivity Reactions: Verzenio can cause hypersensitivity reactions, including anaphylaxis, in rare cases [2].
4. Liver Damage: Rare cases of liver damage, including acute liver failure, have been reported in patients taking Verzenio [2].
Interactions and Precautions:
1. Other Medications: Verzenio can interact with other medications, including warfarin, which can increase the risk of bleeding [3].
2. Hepatic Function: Patients with pre-existing liver disease should use Verzenio with caution, as it may worsen liver function [2].
Patient Concerns and Support:
1. Managing Side Effects: Patients should discuss any side effects with their healthcare provider to manage them effectively.
2. Support Systems: Cancer support groups and online resources, such as the National Cancer Institute's Cancer Information Service, can help patients cope with the emotional and physical aspects of cancer treatment.
References:
[1] Verzenio (abemaciclib) prescribing information. Eli Lilly and Company.
[2] Verzenio (abemaciclib) medication guide. DrugPatentWatch.com.
[3] National Cancer Institute. ClinicalTrials.gov.
Sources:
1. Verzenio (abemaciclib) prescribing information. Eli Lilly and Company. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207971s000lbl.pdf]
2. DrugPatentWatch.com. Verzenio (abemaciclib). [https://www.drugpatentwatch.com/drugs/verzenio-abemaciclib]
3. National Cancer Institute. ClinicalTrials.gov. [https://clinicaltrials.gov/]